Pathways to improving combined modality therapy for stage III nonsmall-cell lung cancer
Conclusion
For locally advanced, inoperable NSCLC, standard therapy has evolved from TRT alone to combined modality therapy. We summarize the recent clinical trial experience and outline promising areas of investigation in an era of greater molecular and immunologic understanding of cancer care.
Source: Annals of Oncology - Category: Cancer & Oncology Authors: Schild, S. E., Vokes, E. E. Tags: reviews Source Type: research
More News: Allergy & Immunology | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Lung Cancer | Non-Small Cell Lung Cancer | Proton Therapy | Study | Toxicology